Table 3.

Characteristics of patients with R/R FLT3-ITD AML (n = 160).

Characteristics	R/R FLT3-ITD AML n = 160 (100%)
Age (years)
Median (IQR)	58.6 (44.8–69.7)
≥ 75: n (%)	18 (11.6)
Sex: n (%)
Male	79 (49.4)
Female	81 (50.6)
Status: n (%)
Refractory	46 (28.8)
One induction course	26 (16.3)
Two induction courses	20 (12.5)
Relapse	114 (71.3)
< 6 months	46 (28.8)
≥ 6 months	68 (42.5)
Duration of CR1 or CRi1 (months)
Median (IQR)	7.2 (4.3–12.6)
Allogeneic HSCT history: n (%)
	28 (17.5)
Previous midostaurin or sorafenib: n (%)
	0 (0)

IQR, interquartile range; CR, complete remission; CRi, CR with incomplete hematological recovery, AML, acute myeloid leukemia.